Kingworld Medicines Group Limited Fundamental Analysis
Kingworld Medicines Group Limited Fundamental Analysis
Kingworld Medicines Group Limited (1110.HK) shows weak financial fundamentals with a PE ratio of 16.86, profit margin of 1.23%, and ROE of 1.83%. The company generates $0.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 26.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1110.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1110.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1110.HK trades at attractive valuation levels.
Growth Score
Moderate1110.HK shows steady but slowing expansion.
Financial Health Score
Excellent1110.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1110.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1110.HK Expensive or Cheap?
P/E Ratio
1110.HK trades at 16.86 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 1110.HK's PEG of -0.26 indicates potential undervaluation.
Price to Book
The market values Kingworld Medicines Group Limited at 0.30 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.20 times EBITDA. This is generally considered low.
How Well Does 1110.HK Make Money?
Net Profit Margin
For every $100 in sales, Kingworld Medicines Group Limited keeps $1.23 as profit after all expenses.
Operating Margin
Core operations generate 6.89 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.83 in profit for every $100 of shareholder equity.
ROA
Kingworld Medicines Group Limited generates $0.78 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kingworld Medicines Group Limited generates limited operating cash flow of $83.42M, signaling weaker underlying cash strength.
Free Cash Flow
Kingworld Medicines Group Limited produces free cash flow of $54.18M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.09 in free cash annually.
FCF Yield
1110.HK converts 29.85% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.86
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.26
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.30
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.20
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.70
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.008
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How 1110.HK Stacks Against Its Sector Peers
| Metric | 1110.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.86 | 29.63 | Better (Cheaper) |
| ROE | 1.83% | 223.00% | Weak |
| Net Margin | 1.23% | -38669.00% (disorted) | Weak |
| Debt/Equity | 0.70 | 0.82 | Neutral |
| Current Ratio | 1.09 | 4.30 | Neutral |
| ROA | 0.78% | -379.00% (disorted) | Weak |
1110.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kingworld Medicines Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation